慢性阻塞性肺疾病（COPD）的药物治疗及当前争议
Pharmacological treatment and current controversies in COPD.
作者信息
Cazzola Mario, Rogliani Paola, Stolz Daiana, Matera Maria Gabriella
机构信息
Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.
Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital of Basel, Basel, Switzerland.
出版信息
F1000Res. 2019 Aug 29;8. doi: 10.12688/f1000research.19811.1. eCollection 2019.
Abstract
Bronchodilators, corticosteroids, and antibiotics are still key elements for treating chronic obstructive pulmonary disease in the 2019 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations and this is due in part to our current inability to discover new drugs capable of decisively influencing the course of the disease. However, in recent years, information has been produced that, if used correctly, can allow us to improve the use of the available therapies.
摘要
支气管扩张剂、皮质类固醇和抗生素仍然是2019年慢性阻塞性肺疾病全球倡议（GOLD）推荐的治疗慢性阻塞性肺疾病的关键要素，部分原因在于我们目前无法发现能够决定性地影响该疾病进程的新药。然而，近年来已产生了一些信息，如果正确使用，这些信息能够让我们改进现有疗法的使用。
相似文献
1
Pharmacological treatment and current controversies in COPD.
F1000Res. 2019 Aug 29;8. doi: 10.12688/f1000research.19811.1. eCollection 2019.
2
Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.
NPJ Prim Care Respir Med. 2017 Jun 29;27(1):43. doi: 10.1038/s41533-017-0040-z.
3
Overuse of long-acting β-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns.
Postgrad Med. 2023 Nov;135(8):784-802. doi: 10.1080/00325481.2023.2284650. Epub 2024 Jan 10.
4
Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.
NPJ Prim Care Respir Med. 2017 Feb 24;27(1):13. doi: 10.1038/s41533-016-0009-3.
5
What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?
Expert Rev Respir Med. 2013 Apr;7(2 Suppl):43-51. doi: 10.1586/ers.13.17.
6
Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Int J Chron Obstruct Pulmon Dis. 2012;7:201-9. doi: 10.2147/COPD.S25805. Epub 2012 Mar 15.
7
Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease.
COPD. 2016 Oct;13(5):540-6. doi: 10.3109/15412555.2016.1141877. Epub 2016 Mar 2.
8
Current drug treatment, chronic and acute.
Clin Chest Med. 2014 Mar;35(1):177-89. doi: 10.1016/j.ccm.2013.09.009.
9
Emerging trends in the therapy of COPD: bronchodilators as mono- and combination therapies.
Drug Discov Today. 2007 Jun;12(11-12):472-8. doi: 10.1016/j.drudis.2007.04.003. Epub 2007 Apr 26.
引用本文的文献
1
Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Respir Res. 2023 Jul 31;24(1):194. doi: 10.1186/s12931-023-02500-8.
2
Matrix Metalloproteinases in Chronic Obstructive Pulmonary Disease.
Int J Mol Sci. 2023 Feb 14;24(4):3786. doi: 10.3390/ijms24043786.
3
Extract Alleviates COPD by Inhibiting the Inflammatory Response via Downregulation of NF-κB.
Molecules. 2022 Nov 26;27(23):8243. doi: 10.3390/molecules27238243.
4
Analysis of the Clinical Efficacy and Molecular Mechanism of Xuefu Zhuyu Decoction in the Treatment of COPD Based on Meta-Analysis and Network Pharmacology.
Comput Math Methods Med. 2022 Nov 26;2022:2615580. doi: 10.1155/2022/2615580. eCollection 2022.
5
Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on β2 adrenoceptor.
Pharmacol Res Perspect. 2022 Oct;10(5):e00994. doi: 10.1002/prp2.994.
6
Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score.
J Clin Med. 2022 Aug 1;11(15):4491. doi: 10.3390/jcm11154491.
7
Interclass Difference in Pneumonia Risk in COPD Patients Initiating Fixed Dose Inhaled Treatment Containing Extrafine Particle Beclometasone versus Fine Particle Fluticasone.
Int J Chron Obstruct Pulmon Dis. 2022 Feb 15;17:355-370. doi: 10.2147/COPD.S342357. eCollection 2022.
8
Beyond Dual Bronchodilation - Triple Therapy, When and Why.
Int J Chron Obstruct Pulmon Dis. 2022 Jan 14;17:165-180. doi: 10.2147/COPD.S345263. eCollection 2022.
9
Identification of Potential Key Genes in the Pathogenesis of Chronic Obstructive Pulmonary Disease Through Bioinformatics Analysis.
Front Genet. 2021 Nov 3;12:754569. doi: 10.3389/fgene.2021.754569. eCollection 2021.
10
An Overview of the Safety and Efficacy of Monoclonal Antibodies for the Chronic Obstructive Pulmonary Disease.
Biologics. 2021 Aug 27;15:363-374. doi: 10.2147/BTT.S295409. eCollection 2021.
本文引用的文献
1
Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics.
Trends Pharmacol Sci. 2019 Jul;40(7):452-463. doi: 10.1016/j.tips.2019.04.015. Epub 2019 May 27.
2
Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Respir Res. 2019 May 27;20(1):104. doi: 10.1186/s12931-019-1078-y.
3
Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways.
Pulm Pharmacol Ther. 2019 Jun;56:39-50. doi: 10.1016/j.pupt.2019.03.004. Epub 2019 Mar 12.
4
Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report.
Eur Respir J. 2019 May 9;53(5). doi: 10.1183/13993003.02058-2018. Print 2019 May.
5
Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.
Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17.
6
Inhaled corticosteroids in COPD: the final verdict is….
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01940-2018. Print 2018 Dec.
7
Triple therapy single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis.
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01586-2018. Print 2018 Dec.
8
POINT: Should LAMA/LABA Combination Therapy Be Used as Initial Maintenance Treatment for COPD? Yes.
Chest. 2018 Oct;154(4):746-748. doi: 10.1016/j.chest.2018.06.022.
9
Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Lancet Respir Med. 2018 Nov;6(11):827-836. doi: 10.1016/S2213-2600(18)30331-X. Epub 2018 Sep 14.
10
Inhaled corticosteroid containing combinations and mortality in COPD.
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01230-2018. Print 2018 Dec.
Zotero 插件